Search
Orchestra Biomed Holdings Inc
OBIOAdd to Watchlist
4.190USD
-0.110-2.56%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
238.97MMarket Cap
LossP/E TTM
More Details of Orchestra Biomed Holdings Inc Company
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.
Orchestra Biomed Holdings Inc Info
Ticker SymbolOBIO
Company nameOrchestra Biomed Holdings Inc
IPO dateAug 04, 2020
CEOHochman (David P)
Number of employees70
Security typeOrdinary Share
Fiscal year-endAug 04
Address150 Union Square Drive
CityNEW HOPE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code18938
Phone16463439298
Website
Ticker SymbolOBIO
IPO dateAug 04, 2020
CEOHochman (David P)
Company Executives of Orchestra Biomed Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Hochman
Mr. David P. Hochman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
612.64K
+0.28%
Mr. Andrew Lawrence Taylor
Mr. Andrew Lawrence Taylor
Chief Financial Officer
Chief Financial Officer
191.40K
-18.99%
Dr. Eric S. Fain, M.D.
Dr. Eric S. Fain, M.D.
Lead Independent Director
Lead Independent Director
59.23K
+8.31%
Mr. John Mack
Mr. John Mack
Independent Director
Independent Director
51.85K
+60.06%
Ms. Pamela Ann Connealy
Ms. Pamela Ann Connealy
Independent Director
Independent Director
51.04K
+33.95%
Mr. David Pacitti
Mr. David Pacitti
Independent Director
Independent Director
38.67K
+35.02%
Mr. Jason Aryeh
Mr. Jason Aryeh
Independent Director
Independent Director
--
--
Mr. Darren R. Sherman
Mr. Darren R. Sherman
President, Chief Operating Officer, Director
President, Chief Operating Officer, Director
--
--
Mr. Christopher (Chris) Cleary
Mr. Christopher (Chris) Cleary
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. David P. Hochman
Mr. David P. Hochman
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
612.64K
+0.28%
Mr. Andrew Lawrence Taylor
Mr. Andrew Lawrence Taylor
Chief Financial Officer
Chief Financial Officer
191.40K
-18.99%
Dr. Eric S. Fain, M.D.
Dr. Eric S. Fain, M.D.
Lead Independent Director
Lead Independent Director
59.23K
+8.31%
Mr. John Mack
Mr. John Mack
Independent Director
Independent Director
51.85K
+60.06%
Ms. Pamela Ann Connealy
Ms. Pamela Ann Connealy
Independent Director
Independent Director
51.04K
+33.95%
Mr. David Pacitti
Mr. David Pacitti
Independent Director
Independent Director
38.67K
+35.02%
FAQs
Who are the top five shareholders of Orchestra Biomed Holdings Inc?
The top five shareholders of Orchestra Biomed Holdings Inc are: Mr. David P. Hochman
How many institutions hold shares of Orchestra Biomed Holdings Inc (OBIO)?
As of 2026Q1, 162 institutions hold shares of Orchestra Biomed Holdings Inc, with a combined market value of approximately 24.76M, accounting for 42.19% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2163850.00.